Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium

Journal of Medical Economics

Volumn 13, Issue 3, 2010, Pages 537-551

  Annemans, L ^a,b   Bresse, X ^c,d   Gobbo, C ^c,d   Papageorgiou, M ^d  

^a GHENT UNIVERSITY   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c SANOFI PASTEUR   (France)

^d Uxbridge ^*  (United Kingdom)

Author keywords

Belgium; Cost effectiveness; Herpes zoster; Post herpetic neuralgia; Vaccination

Indexed keywords

VARICELLA ZOSTER VACCINE;

ARTICLE; BELGIUM; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; POSTHERPETIC NEURALGIA; QUALITY ADJUSTED LIFE YEAR; VACCINATION;

AGED; ANALYSIS OF VARIANCE; BELGIUM; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INCIDENCE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NEURALGIA, POSTHERPETIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77956686261     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.502854     Document Type: Article

References (45)

1. Miller E, Marshall R, Vurdien JE. Epidemiology, outcome and control of varicella-zoster virus infection. Rev Med Microbiol 1993;4:222-230
2. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. Br Med J 2000;321:778-779
3. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127: 305-314
4. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-1349
5. Johnson R, McElhaney J, Pedalino B, et al. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007;11:S43-48 (Pubitemid 350302067)
6. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster -Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57:1-40
7. Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002;19:471-475
8. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-354
9. Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007;7: 1581-1595
10. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975;25: 571-575
11. Schmader K, Gnann Jr. JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197:S207-215
12. Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis 1999;28:736-739
13. Volpi A, Gatti A, Pica F, et al. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008;80:1646-1652
14. Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol 1997;36:667-672
15. Chidiac C, Bruxelle J, Daures JP, et al.Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001;33: 62-69
16. SchmittS, Weinke T, EdteA, et al.Herpes zoster and post-herpetic neuralgia seriously impact patients' quality of daily life. 19th IAGG World Congress of Gerontology and Geriatrics (IAGG). Paris, France, July 5-9, 2009 (Abstract)
17. Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004;39:342-348
18. Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005;6:356-363
19. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352: 2271-2284
20. Centers for Disease Control and Prevention. Prevention of Herpes Zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57
21. Advisory Committee on Immunization Practices (ACIP). Recommended Adult Immunization Schedule -United States, October 2007-September 2008. 2010
22. Austrian Superior Sanitary Council, Vaccination Committee March 2nd, 2010. http://www.bmg.gv.at/cms/site/attachments/1/4/0/CH0780/CMS10389130 10412/impfplan-2010-korr-maerz.pdf
23. Cleemput I, van Wilder P, Vrijens F. Guidelines for pharmacoeconomic evaluations in Belgium. Brussels: KCE reports 78 C, 2008
24. Weinstein MC, O'Brien B, Hornberger J. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices -Modeling Studies. Value Health 2003;6:9-17
25. Nagasako EM, Johnson RW, Griffin DR, et al. Rash severity in herpes zoster: Correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol 2002;46:834-839
26. Caekelbergh K, Lamotte M, Muchada JP. Management of herpes zoster and post-herpetic neuralgia in Belgium: a cost of illness study. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Athens, Greece (Abstract)
27. Sabbe M, Van Casteren V. Netwerk van Huisartsenpeilpraktijken, Wetenschappelijk Instituut voor Volksgezondheid, 2008. Persoonlijke mede-deling, 2008
28. Sentinel General Practitioners -Scientific Institute of Public Health of Belgium. http://www.iph.fgov.be/epidemio/epien/index10.htm. 2010
29. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2008;137:38-47
30. Statistics Belgium. (2008). Belgian population data 01/01/2006. 2010
31. Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax®. Clin Vaccine Immunol 2008;15:314-319
32. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007;55: 1499-1507
33. Schmader K, Oxman MN, Levin M. Persistence of zoster vaccine efficacy. Poster presented at the 48th annual ICAAC/IDSA 46th annual meeting, Washington DC, USA, 25-28 October. Poster number G-409 (Abstract)
34. Szende A, Williams A. Measuring self-reported population health: an international perspective based on EQ-5D. Budapest, Hungary: SpringMed Publishing Limited, 2004
35. Cleemput I, Kind P, Kesteloot K. Rescaling social preference data: implications for modelling. In: Kind P, Macran S, eds. 19th Plenary Meeting of the EuroQol Group Discussion Papers York: Centre for Health Economics, University of York, 2004:13-123
36. McDermott AM, Toelle TR, Rowbotham DJ. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10:127-135
37. Statistics Belgium (2008). Employment rates 2007/2004. 2008
38. SECUREX Social Management. (2004). Het Absenteisme in Belgie 2004. Kosten, benchmarks, medische redenen en personeelstevredenheid, 2004
39. Rodriguez MJ, Diaz S, Vera-Llonch M. Cost-effectiveness analysis of prega-balin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-2596
40. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-3090
41. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007;25:8326-8337
42. Bala MV, Wood LL, Zarkin GA. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998;51:667-676
43. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004;5:344-356
44. van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27:1454-1467
45. Dworkin RH, Gnann Jr. JW, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008;9:S37-44